Pulmonx (NASDAQ:LUNG) Releases Quarterly Earnings Results, Beats Expectations By $0.07 EPS

Pulmonx (NASDAQ:LUNG) posted its quarterly earnings results on Tuesday. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.07, FiscalAI reports. Pulmonx had a negative return on equity of 96.66% and a negative net margin of 55.03%. The company had revenue of $22.84 million for the quarter, compared to analyst estimates of $21.93 million.

Here are the key takeaways from Pulmonx’s conference call:

• Pulmonx returned to revenue growth in Q3 2026, with worldwide revenue up 6% year over year to $22.8 million; U.S. revenue rose 7% and international revenue increased 5%.
• Management reiterated full-year 2026 revenue guidance of $90 million to $92 million and expects growth to continue in Q4, supported by a rebuilt U.S. sales force and a refocused commercial strategy.
• Cost controls produced substantial operating leverage: adjusted EBITDA loss narrowed nearly 60% to $3.5 million, operating expenses fell 18%, and full-year cash burn is now expected to decline 30% to approximately $22 million.
• Gross margin improved to 76% in Q3, with full-year guidance raised to approximately 77%; management expects margins above 75% to support further leverage as revenue grows.
• China commercial activity is expected to resume by late 2026 or early 2027 following renewal of its registration certificate, but management emphasized that China represents only about 2% of expected business and may be lumpy; AeriSeal enrollment remains on track, with meaningful European revenue anticipated primarily from 2028.

Pulmonx Stock Performance

LUNG stock traded up $0.03 during trading on Tuesday, hitting $1.98. The company had a trading volume of 442,765 shares, compared to its average volume of 472,060. The firm has a 50-day moving average price of $2.02 and a 200-day moving average price of $1.65. The company has a quick ratio of 3.52, a current ratio of 4.32 and a debt-to-equity ratio of 0.95. The firm has a market cap of $85.04 million, a PE ratio of -1.71 and a beta of 0.33. Pulmonx has a 1-year low of $1.13 and a 1-year high of $2.89.

Insiders Place Their Bets

In other news, CEO Glendon E. French III sold 41,882 shares of the business’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $2.26, for a total value of $94,653.32. Following the transaction, the chief executive officer owned 1,137,936 shares of the company’s stock, valued at approximately $2,571,735.36. The trade was a 3.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel David Lehman sold 14,334 shares of the company’s stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $2.26, for a total value of $32,394.84. Following the sale, the general counsel owned 361,827 shares of the company’s stock, valued at $817,729.02. This trade represents a 3.81% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 78,340 shares of company stock valued at $177,048. 7.50% of the stock is owned by company insiders.

Analyst Ratings Changes

Separately, Weiss Ratings raised Pulmonx from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 25th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Pulmonx currently has a consensus rating of “Moderate Buy” and an average target price of $7.67.

About Pulmonx

Pulmonx Corporation is a medical device company focused on developing minimally invasive treatments for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company’s technologies are designed to reduce hyperinflation in damaged portions of the lung and help improve breathing, exercise capacity and quality of life.

Pulmonx’s primary product is the Zephyr Endobronchial Valve, a bronchoscopically implanted, one-way valve intended for certain patients with severe emphysema.